FANCL
(Fanconi Anemia, Complementation Group L (FANCL))
Protein Region
Middle Region
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
Attributs du produit
This is a synthetic peptide designed for use in combination with anti-FANCL antibody (Catalog #: ARP56321_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Each Investigator should determine their own optimal working dilution for specific applications.
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Concentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Conseil sur la manipulation
Avoid repeated freeze-thaw cycles.
Stock
-20 °C
Stockage commentaire
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Antigène
FANCL
(Fanconi Anemia, Complementation Group L (FANCL))
Synonymes
FAAP43 Peptide, PHF9 Peptide, POG Peptide, 2010322C19Rik Peptide, AW554273 Peptide, B230118H11Rik Peptide, Phf9 Peptide, Pog Peptide, gcd Peptide, Fanconi anemia complementation group L Peptide, Fanconi anemia, complementation group L Peptide, FANCL Peptide, Fancl Peptide
Sujet
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FAN
Alias Symbols: FAAP43, FLJ10335, PHF9, POG
Protein Interaction Partner: ACVR1,BMPR1B,C17orf70,GGN,HES1,TGFBR1,FANCA,FANCM,YDL160C-A,YOL086W-A